CRISPR-Cas9 can be delivered directly into the eye of living animals to treat age-related macular degeneration efficiently and safely, report scientists.
CRISPR-Cas9 can be delivered directly into the eye of living animals to treat age-related macular degeneration efficiently and safely, report scientists.